http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html <ul class="bwlistdisc"> <li> <i>Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing</i> </li> <li> <i>Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed</i> </li> <li> <i>Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration</i> </li> <li> <i>Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control</i> </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced encouraging updated clinical data from the ongoing OTC-HOPE clinical trial evaluating http://www.streetinsider.com/Press+Releases/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html Thu, 27 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/Press+Releases/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html <ul class="bwlistdisc"> <li> <i>Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing</i> </li> <li> <i>Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed</i> </li> <li> <i>Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration</i> </li> <li> <i>Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control</i> </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced encouraging updated clinical data from the ongoing OTC-HOPE clinical trial evaluating http://www.streetinsider.com/Press+Releases/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html Thu, 27 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/Business+Wire/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html <ul class="bwlistdisc"> <li> <i>Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing</i> </li> <li> <i>Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed</i> </li> <li> <i>Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration</i> </li> <li> <i>Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control</i> </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced encouraging updated clinical data from the ongoing OTC-HOPE clinical trial evaluating http://www.streetinsider.com/Business+Wire/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html Thu, 27 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/Business+Wire/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html <ul class="bwlistdisc"> <li> <i>Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing</i> </li> <li> <i>Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events observed</i> </li> <li> <i>Updated low-dose cohort data demonstrate a 74% reduction in annualized hyperammonemic crises (HACs), the most serious and life-threatening manifestation of the condition, following ECUR-506 administration</i> </li> <li> <i>Low-dose cohort data provide evidence of targeted hepatic editing and improved metabolic control</i> </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced encouraging updated clinical data from the ongoing OTC-HOPE clinical trial evaluating http://www.streetinsider.com/Business+Wire/iECURE+Presents+Updated+Clinical+Data+from+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+2026/26984963.html Thu, 27 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECISION+BIOSCIENCES++++++++++++++++++Filed+by%3A+Weinstein+Benjamin/26967631.html si-local-file:///var/storage/secattach/20260824/26967631.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECISION+BIOSCIENCES++++++++++++++++++Filed+by%3A+Weinstein+Benjamin/26967631.html Mon, 24 Aug 2026 15:13:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECISION+BIOSCIENCES++++++++++++++++++Filed+by%3A+Weinstein+Benjamin/26967631.html si-local-file:///var/storage/secattach/20260824/26967631.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PRECISION+BIOSCIENCES++++++++++++++++++Filed+by%3A+Weinstein+Benjamin/26967631.html Mon, 24 Aug 2026 15:13:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Aug+24/26964074.html si-local-file:///var/storage/secattach/20260824/26964074.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Aug+24/26964074.html Mon, 24 Aug 2026 07:01:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Aug+24/26964074.html si-local-file:///var/storage/secattach/20260824/26964074.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PRECISION+BIOSCIENCES+++++For%3A+Aug+24/26964074.html Mon, 24 Aug 2026 07:01:00 -0400 DTIL O.20406057 http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html <p>Precision BioSciences, Inc. (Nasdaq: DTIL) announced that it dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial, evaluating PBGENE-DMD as a treatment for Duchenne muscular dystrophy (DMD).</p> <p>The first patient was dosed at Arkansas Children's Hospital, a Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Care Center and designated Muscular Dystrophy Association Care Center. The company said it expects to report initial safety data by year-end 2026.</p> <p>PBGENE-DMD uses two ARCUS nucleases delivered in a single adeno-associated virus to excise exons 45-55 of the dystrophin gene, with the aim of restoring a near full-length functional dystrophin protein. According to http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html Mon, 24 Aug 2026 06:01:19 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html <p>Precision BioSciences, Inc. (Nasdaq: DTIL) announced that it dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial, evaluating PBGENE-DMD as a treatment for Duchenne muscular dystrophy (DMD).</p> <p>The first patient was dosed at Arkansas Children's Hospital, a Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Care Center and designated Muscular Dystrophy Association Care Center. The company said it expects to report initial safety data by year-end 2026.</p> <p>PBGENE-DMD uses two ARCUS nucleases delivered in a single adeno-associated virus to excise exons 45-55 of the dystrophin gene, with the aim of restoring a near full-length functional dystrophin protein. According to http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html Mon, 24 Aug 2026 06:01:19 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html <p>Precision BioSciences, Inc. (Nasdaq: DTIL) announced that it dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial, evaluating PBGENE-DMD as a treatment for Duchenne muscular dystrophy (DMD).</p> <p>The first patient was dosed at Arkansas Children's Hospital, a Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Care Center and designated Muscular Dystrophy Association Care Center. The company said it expects to report initial safety data by year-end 2026.</p> <p>PBGENE-DMD uses two ARCUS nucleases delivered in a single adeno-associated virus to excise exons 45-55 of the dystrophin gene, with the aim of restoring a near full-length functional dystrophin protein. According to http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html Mon, 24 Aug 2026 06:01:19 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html <p>Precision BioSciences, Inc. (Nasdaq: DTIL) announced that it dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial, evaluating PBGENE-DMD as a treatment for Duchenne muscular dystrophy (DMD).</p> <p>The first patient was dosed at Arkansas Children's Hospital, a Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Care Center and designated Muscular Dystrophy Association Care Center. The company said it expects to report initial safety data by year-end 2026.</p> <p>PBGENE-DMD uses two ARCUS nucleases delivered in a single adeno-associated virus to excise exons 45-55 of the dystrophin gene, with the aim of restoring a near full-length functional dystrophin protein. According to http://www.streetinsider.com/FDA/Precision+BioSciences+doses+first+patient+in+DMD+gene-editing+trial/26963668.html Mon, 24 Aug 2026 06:01:19 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Press+Releases/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html <p class="bwalignc"> <i>-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD –</i> </p><p class="bwalignc"> <i>-First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center–</i> </p> <p> DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop <i>in vivo</i> gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). </p><p> PBGENE-DMD is Precision's wholly owned <i>in vivo</i> gene http://www.streetinsider.com/Business+Wire/Precision+BioSciences+Commences+Dosing+in+Phase+12+FUNCTION-DMD+Study/26963667.html Mon, 24 Aug 2026 06:01:00 -0400 A.06822034 DTIL O.20026344 O.20406057 http://www.streetinsider.com/Press+Releases/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 for neonatal-onset ornithine transcarbamylase (OTC) deficiency will be featured in an oral presentation at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM), taking place August 25-28, 2026, in Helsinki, Finland. </p><p> The presentation will include updated safety observations from the ongoing OTC-HOPE study, and genome editing data on measures of metabolic control from the low-dose cohort. Additional analyses http://www.streetinsider.com/Press+Releases/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html Thu, 20 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/Press+Releases/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 for neonatal-onset ornithine transcarbamylase (OTC) deficiency will be featured in an oral presentation at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM), taking place August 25-28, 2026, in Helsinki, Finland. </p><p> The presentation will include updated safety observations from the ongoing OTC-HOPE study, and genome editing data on measures of metabolic control from the low-dose cohort. Additional analyses http://www.streetinsider.com/Press+Releases/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html Thu, 20 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/Business+Wire/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 for neonatal-onset ornithine transcarbamylase (OTC) deficiency will be featured in an oral presentation at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM), taking place August 25-28, 2026, in Helsinki, Finland. </p><p> The presentation will include updated safety observations from the ongoing OTC-HOPE study, and genome editing data on measures of metabolic control from the low-dose cohort. Additional analyses http://www.streetinsider.com/Business+Wire/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html Thu, 20 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/Business+Wire/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html <p> PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic, <i>in vivo</i> targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 for neonatal-onset ornithine transcarbamylase (OTC) deficiency will be featured in an oral presentation at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM), taking place August 25-28, 2026, in Helsinki, Finland. </p><p> The presentation will include updated safety observations from the ongoing OTC-HOPE study, and genome editing data on measures of metabolic control from the low-dose cohort. Additional analyses http://www.streetinsider.com/Business+Wire/iECURE+to+Present+Clinical+Data+from+Ongoing+OTC-HOPE+Trial+of+ECUR-506+in+Neonatal-Onset+Ornithine+Transcarbamylase+Deficiency+at+SSIEM+Annual+Symposium/26953104.html Thu, 20 Aug 2026 08:00:00 -0400 DTIL O.20406057 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PRECISION+BIOSCIENCES++++++++++++++++/26888098.html si-local-file:///var/storage/secattach/20260807/26888098.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PRECISION+BIOSCIENCES++++++++++++++++/26888098.html Fri, 07 Aug 2026 08:35:00 -0400 DTIL O.20406057